Happify Launches the First Prescription Digital Therapeutics to Treat Both MDD and GAD
NEW YORK--(BUSINESS WIRE)--Happify Health, a global software-enabled healthcare platform, today announced the launch of Ensemble, the first and only transdiagnostic prescription digital therapeutic for the treatment of patients who have Major Depressive Disorder (MDD) or Generalized Anxiety Disorder (GAD).
Designed as an adjunct to care for MDD and GAD, Ensemble must be prescribed by a clinician to treat these disorders. It is accessible via smartphone or computer, and teaches patients new skills and habits to take control of their anxiety and depression. “The worldwide epidemic of depression and anxiety rages on, affecting 1 in 5 people—but between 30-40% of those needing treatment for these disorders do not receive it for one reason or another,” said Dr. Acacia Parks, Chief Science Officer of Happify Health. “There are research-validated approaches for addressing depression and anxiety, but getting those approaches to the general public is a massive challenge that Happify Health is serious about tackling.”
“Data shows that people with MDD are 5.7 times more likely to have GAD than people without MDD. Additionally, 20% of people with major depressive disorder also meet …
More on: www.businesswire.com